Dianthus Therapeutics (DNTH) Competitors $20.61 -0.48 (-2.28%) Closing price 04:00 PM EasternExtended Trading$20.66 +0.05 (+0.27%) As of 06:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock DNTH vs. IBRX, GMTX, ARWR, APLS, TWST, NAMS, APGE, RXRX, DNLI, and INDVShould you be buying Dianthus Therapeutics stock or one of its competitors? The main competitors of Dianthus Therapeutics include ImmunityBio (IBRX), Gemini Therapeutics (GMTX), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), Twist Bioscience (TWST), NewAmsterdam Pharma (NAMS), Apogee Therapeutics (APGE), Recursion Pharmaceuticals (RXRX), Denali Therapeutics (DNLI), and Indivior (INDV). These companies are all part of the "pharmaceutical products" industry. Dianthus Therapeutics vs. Its Competitors ImmunityBio Gemini Therapeutics Arrowhead Pharmaceuticals Apellis Pharmaceuticals Twist Bioscience NewAmsterdam Pharma Apogee Therapeutics Recursion Pharmaceuticals Denali Therapeutics Indivior Dianthus Therapeutics (NASDAQ:DNTH) and ImmunityBio (NASDAQ:IBRX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations. Does the media prefer DNTH or IBRX? In the previous week, Dianthus Therapeutics had 2 more articles in the media than ImmunityBio. MarketBeat recorded 9 mentions for Dianthus Therapeutics and 7 mentions for ImmunityBio. Dianthus Therapeutics' average media sentiment score of 0.99 beat ImmunityBio's score of 0.18 indicating that Dianthus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dianthus Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ImmunityBio 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in DNTH or IBRX? 47.5% of Dianthus Therapeutics shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 8.2% of Dianthus Therapeutics shares are owned by insiders. Comparatively, 76.8% of ImmunityBio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts recommend DNTH or IBRX? Dianthus Therapeutics currently has a consensus target price of $53.00, suggesting a potential upside of 157.16%. ImmunityBio has a consensus target price of $12.25, suggesting a potential upside of 326.83%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts clearly believe ImmunityBio is more favorable than Dianthus Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13ImmunityBio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has higher earnings and valuation, DNTH or IBRX? Dianthus Therapeutics has higher earnings, but lower revenue than ImmunityBio. Dianthus Therapeutics is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDianthus Therapeutics$6.24M106.22-$84.97M-$2.88-7.16ImmunityBio$14.74M171.85-$413.56M-$0.58-4.95 Which has more risk and volatility, DNTH or IBRX? Dianthus Therapeutics has a beta of 1.38, suggesting that its share price is 38% more volatile than the S&P 500. Comparatively, ImmunityBio has a beta of 0.08, suggesting that its share price is 92% less volatile than the S&P 500. Is DNTH or IBRX more profitable? ImmunityBio has a net margin of -1,310.30% compared to Dianthus Therapeutics' net margin of -1,544.23%. ImmunityBio's return on equity of 0.00% beat Dianthus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dianthus Therapeutics-1,544.23% -29.26% -27.87% ImmunityBio -1,310.30%N/A -121.88% SummaryImmunityBio beats Dianthus Therapeutics on 9 of the 16 factors compared between the two stocks. Get Dianthus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DNTH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding DNTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DNTH vs. The Competition Export to ExcelMetricDianthus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$678.25M$2.96B$5.56B$9.04BDividend YieldN/A2.42%5.25%4.03%P/E Ratio-7.168.0519.5820.23Price / Sales106.22296.11442.27127.79Price / CashN/A42.7337.5058.41Price / Book1.737.748.085.60Net Income-$84.97M-$54.96M$3.16B$248.43M7 Day Performance7.82%6.04%3.77%5.15%1 Month Performance9.92%4.47%3.90%7.62%1 Year Performance-28.04%6.12%34.22%21.56% Dianthus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DNTHDianthus Therapeutics1.6122 of 5 stars$20.61-2.3%$53.00+157.2%-26.3%$678.25M$6.24M-7.1680High Trading VolumeIBRXImmunityBio2.4475 of 5 stars$2.72flat$12.25+350.4%-57.1%$2.40B$14.74M-4.69590Analyst ForecastGMTXGemini TherapeuticsN/A$54.75+3.0%N/A+12.8%$2.37BN/A-54.7530ARWRArrowhead Pharmaceuticals3.7496 of 5 stars$16.84+0.3%$43.71+159.6%-25.5%$2.32B$545.21M-12.03400APLSApellis Pharmaceuticals4.4321 of 5 stars$17.42-4.6%$39.79+128.4%-48.8%$2.29B$781.37M-9.73770TWSTTwist Bioscience3.973 of 5 stars$35.59-6.8%$50.40+41.6%-22.5%$2.29B$312.97M-10.95990NAMSNewAmsterdam Pharma2.3091 of 5 stars$19.46-2.0%$42.89+120.4%+8.2%$2.23B$47.14M-10.354APGEApogee Therapeutics2.9131 of 5 stars$39.24-17.3%$99.00+152.3%-7.7%$2.19BN/A-10.9091Analyst ForecastOptions VolumeHigh Trading VolumeRXRXRecursion Pharmaceuticals1.1833 of 5 stars$4.93-6.5%$7.00+42.0%-24.9%$2.14B$58.84M-2.79400Analyst ForecastOptions VolumeGap UpHigh Trading VolumeDNLIDenali Therapeutics4.7159 of 5 stars$14.25-3.0%$33.71+136.6%-28.4%$2.13B$330.53M-5.34430News CoverageAnalyst RevisionINDVIndivior2.7687 of 5 stars$15.55+0.9%$17.00+9.3%+48.6%$2.12B$1.17B-50.161,051 Related Companies and Tools Related Companies ImmunityBio Alternatives Gemini Therapeutics Alternatives Arrowhead Pharmaceuticals Alternatives Apellis Pharmaceuticals Alternatives Twist Bioscience Alternatives NewAmsterdam Pharma Alternatives Apogee Therapeutics Alternatives Recursion Pharmaceuticals Alternatives Denali Therapeutics Alternatives Indivior Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:DNTH) was last updated on 7/10/2025 by MarketBeat.com Staff From Our PartnersI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | Sponsored"I'm risking my reputation on this"I've stayed quiet for too long, but after everything I've uncovered about what's brewing in the 2025 crypto ma...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free DNTH Stock Alerts